Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland

Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland

Abstract Advances in biologic and targeted synthetic DMARDs have expanded treatment options for spondylarthritis. Despite improvements with TNF inhibitors, many patients remain refractory. Secukinumab, an IL-17A inhibitor, has shown promise in controlled trials. This study evaluates its real-world r...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Felis-Giemza, Małgorzata Stasiek, Karolina Palej, Marta Wysmołek-Sołtysik, Marta Łosoś, Sandra Stańczyk, Joanna Werońska-Tatara, Jakub Wroński
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Spondyloarthritis
Secukinumab
Real-world
Efficacy
Drug survival
Online Access:https://doi.org/10.1038/s41598-025-11070-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-11070-2

Similar Items